Context

Biom’Up : recognized expertise in the field of collagen.

HEMOBLAST: best-in-class active dry powder used to rapidly halt bleeding during surgery (hemostasis).

PMA filed with FDA in June 2017 (approval expected mid-2018) and CE marked.

Leadership team with a track record of execution in Europe and the US.

Backed by leading European life science investors: BPI, Gimv & Lundbeck.

Strategy focused on capturing 15% of the US & EU markets ($1.2bn) within 5 years.

Use of proceeds include the scale-up of US and EU commercial infrastructure, new studies to expand use of Hemoblast and general corporate purposes.

About Biom'Up

Headquartered in France, Biom’Up designs hemostatic products based on patented biopolymers that aim to simplify surgical procedures in numerous specialties (spine, cardiothoracic, general, orthopedic, plastic). Its flagship product, HEMOBLAST™ Bellows, is a unique hemostatic solution, ready to use and is usable once or several times during the surgery. Developed by a world-renowned scientific team, HEMOBLAST™ Bellows has obtained positive results for all the primary and secondary endpoints of Phase III of its pivotal study involving 412 patients in the United States. A PMA (Pre-Market Approval) application for HEMOBLAST™ Bellows was submitted to the FDA (Food & Drug Administration) in July 2017 with a view to obtaining marketing approval in the United States in mid-2018. Since its creation, Biom’Up has benefited from the support of prominent European investors such as Bpifrance, Innobio, GIMV, Lundbeckfond, Mérieux Participation, SHAM and ACG.

Discover Biom'Up

Hervé Ronin

Investment Banking

Dr. Anne Moore

Investment Banking

Pierre Kiecolt-Wahl

Investment Banking

Jean de Pracomtal

Investment Banking

Deal Team

Should you want to know more about this transaction, you can contact one of the team members above

Privacy Preference Center